Kemin Industries, a global manufacturer of ingredients that strives to sustainably transform the quality of life of 80% of the world with its products and services, and its subsidiary Kemin Biologics, have signed an exclusive agreement with Pacific GeneTech (PGT) to licence TMH001 Eimeria vaccine for poultry
PGT is a biologics company that develops and markets next-generation vaccines for areas of high unmet or underserved animal health and food safety needs.
TMH001 is the only inactivated oral vaccine containing highly conserved Apicomplexan antigens and patented Hercules adjuvant containing a novel proprietary Pichia yeast vector. As a cross-protective vaccine on the Eimeria market, it will provide a safe and effective alternative to the use of antibiotics and live-inducing vaccines.
Tim Collard, PGT’s CEO, said, “With its proven commitment to new and sustainable technologies for food security and safety, Kemin was the ideal partner for TMH001. We are thrilled to be working side-by-side with them to bring innovative solutions to market that are needed in the animal health industry.”
Kemin Biologics, a division of Kemin Industries that focuses on developing vaccines as the first line of defence against disease to reduce the use of antibiotics, entered into this partnership with PGT last month. As part of its partnership with PGT, Kemin will focus on the development and registration of the Eimeria vaccine in the US and other countries beginning with the European Union. Kemin will also expand the availability of Eimeria vaccine to Asia, the Middle East, Africa and Latin America.
Dr Chris Nelson, president and CEO of Kemin Industries, said, “Kemin sees great potential in the marketplace for innovative vaccines and is dedicated to improving the health of poultry and livestock which ensures the safety of our global food supply.”
In addition to a high safety profile, TMH001 provides demonstrable cross-protection against five economically important Eimeria species with the potential to protect against more species. TMH001 was developed from the proprietary Aegis vaccine platform of PGT, which produced additional cross-protective vaccines for multiple pathogens. The platform was originally developed by the Poultry Health Laboratory of the University of Arkansas in collaboration with other US universities and supported by the US Department of Agriculture.